Titanium	O
Dioxide	O
Nanoparticles	O
As	O
Guardian	O
against	O
Environmental	O
Carcinogen	O
Benzo	O
[	O
alpha	O
]	O
Pyrene	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
ML	O
AD	O
.	O

Performed	O
the	O
experiments	O
:	O
AD	O
RG	O
QMSJ	O
.	O

Analyzed	O
the	O
data	O
:	O
AD	O
RG	O
ML	O
SSM	O
QR	O
MHS	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
MLBB	O
RG	O
ML	O
.	O

Contributed	O
to	O
the	O
writing	O
of	O
the	O
manuscript	O
:	O
ML	O
AD	O
.	O

Polycyclic	O
aromatic	O
hydrocarbons	O
(	O
PAH	O
),	O
like	O
Benzo	O
[	O
alpha	O
]	O
Pyrene	O
(	O
BaP	O
)	O
are	O
known	O
to	O
cause	O
a	O
number	O
of	O
toxic	O
manifestations	O
including	O
lung	B-DS
cancer	I-DS
.	O

As	O
Titanium	O
dioxide	O
Nanoparticles	O
(	O
TiO2	O
NPs	O
)	O
have	O
recently	O
been	O
shown	O
to	O
adsorb	O
a	O
number	O
of	O
PAHs	O
from	O
soil	O
and	O
water	O
,	O
we	O
investigated	O
whether	O
TiO2	O
NPs	O
could	O
provide	O
protection	O
against	O
the	O
BaP	O
induced	O
toxicity	O
in	O
biological	O
system	O
.	O

A549	O
cells	O
when	O
co	O
-	O
exposed	O
with	O
BaP	O
(	O
25	O
µM	O
,	O
50	O
µM	O
and	O
75	O
µM	O
)	O
along	O
with	O
0	O
.	O
1	O
µg	O
/	O
ml	O
,	O
0	O
.	O
5	O
µg	O
/	O
ml	O
and	O
1	O
µg	O
/	O
ml	O
of	O
TiO2	O
NPs	O
,	O
showed	O
significant	O
reduction	O
in	O
the	O
toxic	O
effects	O
of	O
BaP	O
,	O
as	O
measured	O
by	O
Micronucleus	O
Assay	O
,	O
MTT	O
Assay	O
and	O
ROS	O
Assay	O
.	O

In	O
order	O
to	O
explore	O
the	O
mechanism	O
of	O
protection	O
by	O
TiO2	O
NP	O
against	O
BaP	O
,	O
we	O
performed	O
in	O
silico	O
studies	O
.	O

BaP	O
and	O
other	O
PAHs	O
are	O
known	O
to	O
enter	O
the	O
cell	O
via	O
aromatic	B-GP
hydrocarbon	I-GP
receptor	I-GP
(	O
AHR	B-GP
).	O

TiO2	O
NP	O
showed	O
a	O
much	O
higher	O
docking	O
score	O
with	O
AHR	B-GP
(	O
12074	O
)	O
as	O
compared	O
to	O
the	O
docking	O
score	O
of	O
BaP	O
with	O
AHR	B-GP
(	O
4600	O
).	O

This	O
indicates	O
a	O
preferential	O
binding	O
of	O
TiO2	O
NP	O
with	O
the	O
AHR	B-GP
,	O
in	O
case	O
if	O
both	O
the	O
TiO2	O
NP	O
and	O
BaP	O
are	O
present	O
.	O

Further	O
,	O
we	O
have	O
done	O
the	O
docking	O
of	O
BaP	O
with	O
the	O
TiO2	O
NP	O
bound	O
AHR	B-GP
-	O
complex	O
(	O
score	O
4710	O
),	O
and	O
observed	O
that	O
BaP	O
showed	O
strong	O
adsorption	O
on	O
TiO2	O
NP	O
itself	O
,	O
and	O
not	O
at	O
its	O
original	O
binding	O
site	O
(	O
at	O
AHR	B-GP
).	O

TiO2	O
NPs	O
thereby	O
prevent	O
the	O
entry	O
of	O
BaP	O
in	O
to	O
the	O
cell	O
via	O
AHR	B-GP
and	O
hence	O
protect	O
cells	O
against	O
the	O
deleterious	O
effects	O
induced	O
by	O
BaP	O
.	O

Introduction	O

Human	B-OG
exposure	O
to	O
xenobiotics	O
is	O
almost	O
inevitable	O
.	O

Most	O
of	O
the	O
human	B-OG
cancers	B-DS
are	O
caused	O
due	O
to	O
exposure	O
to	O
xenobiotics	O
including	O
PAHs	O
and	O
hence	O
they	O
are	O
ultimately	O
preventable	O
.	O

PAHs	O
are	O
produced	O
during	O
the	O
combustion	O
processes	O
of	O
organic	O
materials	O
during	O
industrial	O
and	O
other	O
human	B-OG
activities	O
,	O
like	O
processing	O
of	O
coal	O
and	O
crude	O
oil	O
,	O
vehicle	O
traffic	O
and	O
cigarette	O
smoke	O
.	O

PAHs	O
may	O
cause	O
carcinogenesis	O
by	O
damaging	O
the	O
DNA	O
and	O
/	O
or	O
a	O
number	O
of	O
proteins	O
[	O
1	O
].	O

The	O
benzo	O
[	O
a	O
]	O
pyrene	O
(	O
BaP	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
PAHs	O
and	O
is	O
a	O
byproduct	O
of	O
grilled	O
foods	O
,	O
tobacco	O
,	O
cigarette	O
smoke	O
and	O
fuel	O
combustion	O
.	O

BaP	O
has	O
long	O
been	O
correlated	O
to	O
a	O
range	O
of	O
human	B-OG
cancers	B-DS
,	O
predominantly	O
lung	O
and	O
skin	B-DS
cancer	I-DS
[	O
2	O
],	O
[	O
3	O
].	O

The	O
carcinogenic	O
properties	O
of	O
BaP	O
in	O
particular	O
are	O
mostly	O
explained	O
by	O
their	O
capability	O
to	O
induce	O
DNA	O
damage	O
.	O

BaP	O
is	O
the	O
only	O
PAH	O
listed	O
in	O
group	O
1	O
by	O
the	O
International	O
agency	O
for	O
research	O
on	O
cancer	B-DS
[	O
4	O
],	O
and	O
has	O
thus	O
been	O
broadly	O
considered	O
and	O
constitutes	O
the	O
reference	O
compound	O
for	O
assessing	O
toxicity	O
of	O
exposure	O
to	O
mixtures	O
in	O
the	O
toxic	O
equivalent	O
factors	O
approach	O
[	O
5	O
].	O

BaP	O
enters	O
the	O
cell	O
via	O
aryl	B-GP
hydrocarbon	I-GP
receptor	I-GP
(	O
AHR	B-GP
)	O
[	O
6	O
],	O
along	O
with	O
stimulating	O
the	O
AHR	B-GP
to	O
activate	O
transcriptional	O
regulation	O
of	O
xenobiotic	O
response	O
element	O
(	O
XRE	O
)	O
and	O
genes	O
coding	O
for	O
xenobiotic	B-GP
metabolizing	I-GP
enzymes	I-GP
such	O
as	O
cytochrome	B-GP
P450s	I-GP
(	O
CYPs	B-GP
),	O
UDP	B-GP
glucuronosyltransferase	I-GP
UGT1A6	B-GP
,	O
NAD	B-GP
(	I-GP
P	I-GP
)	I-GP
H	I-GP
:	I-GP
quinone	I-GP
oxidoreductase	I-GP
-	I-GP
1	I-GP
(	O
NQO1	B-GP
),	O
aldehyde	B-GP
dehydrogenase	I-GP
(	O
ALDH3A1	B-GP
),	O
and	O
various	O
glutathione	B-GP
-	I-GP
S	I-GP
-	I-GP
transferases	I-GP
[	O
7	O
].	O

After	O
the	O
enzymatic	O
metabolism	O
,	O
BaP	O
is	O
converted	O
to	O
benzo	O
[	O
a	O
]	O
pyrene	O
-	O
7	O
,	O
8	O
-	O
diol	O
-	O
9	O
,	O
10	O
-	O
epoxides	O
(	O
BPDE	O
),	O
a	O
crucial	O
carcinogenic	O
metabolite	O
of	O
BaP	O
,	O
that	O
reacts	O
primarily	O
with	O
the	O
N2	O
position	O
of	O
guanine	O
residues	O
and	O
to	O
a	O
minor	O
coverage	O
with	O
the	O
N6	O
position	O
of	O
adenine	O
residues	O
in	O
DNA	O
[	O
8	O
]	O
to	O
form	O
bulky	O
adducts	O
that	O
block	O
DNA	O
synthesis	O
by	O
replicative	O
or	O
high	O
fidelity	O
DNA	B-GP
polymerases	I-GP
[	O
3	O
].	O

Recently	O
,	O
titanium	O
dioxide	O
nanoparticles	O
have	O
been	O
employed	O
in	O
scavenging	O
the	O
high	O
molecular	O
weight	O
polycyclic	O
aromatic	O
hydrocarbons	O
(	O
PAHs	O
)	O
from	O
the	O
contaminated	O
soils	O
[	O
9	O
].	O

The	O
scavenging	O
capacities	O
of	O
the	O
nanoparticles	O
for	O
PAH	O
and	O
other	O
toxicants	O
could	O
be	O
attributed	O
to	O
their	O
higher	O
affinity	O
towards	O
the	O
xenobiotics	O
due	O
to	O
surface	O
chemistry	O
,	O
large	O
surface	O
area	O
and	O
other	O
intrinsic	O
properties	O
of	O
nanoparticles	O
.	O

Some	O
studies	O
also	O
have	O
shown	O
that	O
titanate	O
nanotube	O
has	O
the	O
capacity	O
to	O
scavenge	O
the	O
PAHs	O
from	O
water	O
sample	O
from	O
the	O
environment	O
[	O
10	O
].	O

The	O
nanoform	O
of	O
TiO2	O
for	O
example	O
titanate	O
nanoSheets	O
(	O
TNS	O
)	O
and	O
titanate	O
nano	O
tubes	O
(	O
TNT	O
)	O
have	O
also	O
been	O
synthesized	O
and	O
used	O
as	O
additives	O
for	O
removing	O
harmful	O
compounds	O
from	O
cigarette	O
smoke	O
[	O
11	O
]	O
including	O
nicotine	O
,	O
tar	O
,	O
ammonia	O
,	O
hydrogen	O
cyanide	O
,	O
selected	O
carbonyls	O
and	O
phenolic	O
compounds	O
.	O

Interestingly	O
,	O
TNT	O
exhibits	O
highly	O
efficient	O
reduction	O
capability	O
for	O
most	O
of	O
the	O
harmful	O
compounds	O
.	O

This	O
might	O
be	O
related	O
to	O
the	O
intrinsic	O
properties	O
of	O
TNT	O
[	O
11	O
].	O

TiO2	O
is	O
a	O
naturally	O
occurring	O
oxide	O
of	O
http	O
://	O
www	O
.	O
absoluteastronomy	O
.	O
com	O
/	O
topics	O
/	O
Titanium	O
titanium	O
,	O
and	O
is	O
biologically	O
inert	O
at	O
lower	O
doses	O
,	O
whereas	O
,	O
at	O
higher	O
doses	O
it	O
may	O
induce	O
slight	O
toxicity	O
and	O
even	O
apoptosis	O
[	O
12	O
].	O

Considering	O
this	O
,	O
we	O
designed	O
the	O
present	O
study	O
in	O
order	O
to	O
explore	O
whether	O
the	O
discussed	O
property	O
of	O
the	O
TiO2	O
NPs	O
could	O
be	O
exploited	O
in	O
the	O
biological	O
system	O
to	O
safeguard	O
against	O
the	O
deleterious	O
effects	O
of	O
PAHs	O
exposure	O
.	O

We	O
also	O
explored	O
the	O
doses	O
of	O
TiO2	O
NPs	O
,	O
at	O
which	O
they	O
provide	O
maximum	O
protection	O
.	O

Further	O
,	O
in	O
silico	O
experiments	O
were	O
also	O
performed	O
using	O
bioinformatics	O
tools	O
,	O
to	O
attain	O
insight	O
of	O
mechanism	O
of	O
protection	O
.	O

Materials	O
and	O
Methods	O

1	O
.	O

Reagents	O
and	O
consumables	O

Most	O
of	O
the	O
specified	O
chemicals	O
,	O
reagents	O
,	O
diagnostic	O
kits	O
etc	O
were	O
purchased	O
from	O
Sigma	O
Chemical	O
Company	O
Pvt	O
.	O

Ltd	O
.	O

(	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
).	O

Cell	O
culture	O
media	O
,	O
PBS	O
,	O
antibiotic	O
-	O
antimycotic	O
were	O
purchased	O
from	O
Hi	O
-	O
Media	O
(	O
Hi	O
-	O
Media	O
Pvt	O
.	O

Ltd	O
.,	O
Mumbai	O
,	O
India	O
).	O

1	O
.	O
1	O
Titanium	O
dioxide	O
Nanoparticles	O

Anatase	O
form	O
of	O
TiO2	O
NPs	O
(	O
d	O
<	O
25	O
nm	O
,	O
specific	O
surface	O
area	O
200	O
–	O
220	O
m2	O
/	O
g	O
)	O
without	O
any	O
coating	O
were	O
purchased	O
from	O
Sigma	O
Aldrich	O
(	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
USA	O
,	O
Cat	O
no	O
.	O
637254	O
).	O

Particles	O
were	O
sterilized	O
by	O
heating	O
to	O
120	O
°	O
C	O
for	O
2	O
h	O
and	O
suspended	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
stock	O
:	O
in	O
1	O
µg	O
/	O
µl	O
PBS	O
).	O

The	O
mean	O
hydrodynamic	O
diameter	O
and	O
zeta	O
potential	O
(	O
ζ	O
)	O
of	O
the	O
TiO2	O
NPs	O
suspension	O
in	O
complete	O
medium	O
as	O
determined	O
by	O
dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
measurement	O
was	O
434	O
.	O
1	O
nm	O
and	O
−	O
7	O
.	O
83	O
mV	O
,	O
respectively	O
,	O
as	O
described	O
previously	O
by	O
us	O
[	O
13	O
].	O

1	O
.	O
2	O
Cell	O
culture	O
and	O
treatment	O
conditions	O

A549	O
cells	O
(	O
lung	B-DS
carcinoma	I-DS
cells	O
)	O
were	O
obtained	O
from	O
the	O
cell	O
bank	O
of	O
NCCS	O
Pune	O
,	O
Maharashtra	O
,	O
India	O
,	O
and	O
were	O
grown	O
in	O
a	O
humidified	O
atmosphere	O
with	O
5	O
%	O
CO2	O
at	O
37	O
°	O
C	O
.	O

The	O
cells	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
'	O
s	O
Medium	O
,	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
and	O
1	O
%	O
antibiotic	O
and	O
anti	O
-	O
mycotic	O
solution	O
,	O
according	O
to	O
the	O
standard	O
procedure	O
.	O

Prior	O
to	O
use	O
in	O
the	O
experiments	O
,	O
cell	O
viability	O
was	O
estimated	O
using	O
trypan	O
blue	O
dye	O
exclusion	O
assay	O
following	O
the	O
protocol	O
as	O
described	O
earlier	O
[	O
14	O
]	O
and	O
batches	O
showing	O
viability	O
more	O
than	O
95	O
%	O
were	O
used	O
for	O
further	O
experiments	O
.	O

2	O
.	O

Dose	O
optimization	O

Different	O
doses	O
of	O
BaP	O
(	O
10	O
µM	O
,	O
25	O
µM	O
,	O
50	O
µM	O
and	O
75	O
µM	O
)	O
were	O
tested	O
in	O
A	O
-	O
549	O
cells	O
for	O
the	O
selection	O
of	O
most	O
suitable	O
doses	O
for	O
various	O
assays	O
in	O
our	O
study	O
.	O

2	O
.	O
1	O
Micronucleus	O
Assay	O

Three	O
different	O
sets	O
of	O
cells	O
were	O
treated	O
with	O
:	O
i	O
)	O
different	O
doses	O
of	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and1	O
.	O
0	O
µg	O
/	O
ml	O
),	O
ii	O
)	O
highest	O
genotoxic	O
dose	O
i	O
.	O
e	O
.	O
25	O
µM	O
of	O
BaP	O
,	O
and	O
iii	O
)	O
co	O
-	O
exposure	O
of	O
BaP	O
(	O
25	O
µM	O
)	O
and	O
different	O
doses	O
of	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
µg	O
/	O
ml	O
,	O
0	O
.	O
5	O
µg	O
/	O
ml	O
,	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
).	O

2	O
.	O
2	O
MTT	O
assay	O

Three	O
different	O
sets	O
of	O
cells	O
for	O
each	O
of	O
three	O
different	O
time	O
periods	O
(	O
6	O
,	O
12	O
and	O
24h	O
)	O
were	O
treated	O
with	O
:	O
i	O
)	O
different	O
doses	O
of	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and1	O
.	O
0	O
µg	O
/	O
ml	O
),	O
ii	O
)	O
highest	O
cytotoxic	O
dose	O
i	O
.	O
e	O
.	O
75	O
µM	O
of	O
BaP	O
,	O
and	O
iii	O
)	O
co	O
-	O
exposure	O
of	O
BaP	O
(	O
75	O
µM	O
)	O
and	O
different	O
doses	O
of	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
µg	O
/	O
ml	O
,	O
0	O
.	O
5	O
µg	O
/	O
ml	O
,	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
).	O

2	O
.	O
3	O
ROS	O
Assay	O

Three	O
different	O
sets	O
of	O
cells	O
for	O
each	O
of	O
four	O
different	O
time	O
periods	O
(	O
2	O
,	O
6	O
,	O
12	O
and	O
24h	O
)	O
were	O
treated	O
with	O
:	O
i	O
)	O
different	O
doses	O
of	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and1	O
.	O
0	O
µg	O
/	O
ml	O
),	O
ii	O
)	O
highest	O
ROS	O
producing	O
dose	O
i	O
.	O
e	O
.	O
50	O
µM	O
of	O
BaP	O
,	O
and	O
iii	O
)	O
co	O
-	O
exposure	O
of	O
BaP	O
(	O
50	O
µM	O
)	O
and	O
different	O
doses	O
of	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
µg	O
/	O
ml	O
,	O
0	O
.	O
5	O
µg	O
/	O
ml	O
,	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
).	O

3	O
.	O

Methodology	O

3	O
.	O
1	O
Micronucleus	O
Assay	O

The	O
genetic	O
damage	O
was	O
assessed	O
by	O
MN	O
assay	O
as	O
described	O
earlier	O
[	O
15	O
].	O

In	O
brief	O
,	O
A549	O
cells	O
were	O
grown	O
on	O
cover	O
slips	O
for	O
24	O
h	O
in	O
6	O
well	O
plates	O
.	O

The	O
cells	O
were	O
exposed	O
to	O
different	O
treatment	O
conditions	O
as	O
discussed	O
and	O
incubated	O
for	O
24h	O
.	O

The	O
cells	O
were	O
fixed	O
in	O
cold	O
fixative	O
and	O
stored	O
at	O
−	O
20	O
°	O
C	O
for	O
at	O
least	O
30	O
min	O
.	O

DNA	O
staining	O
was	O
performed	O
using	O
bisbenzimide	O
(	O
1	O
µg	O
/	O
ml	O
;	O
Hoechst	O
33258	O
;	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
for	O
4	O
min	O
.	O
the	O
cells	O
were	O
washed	O
in	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
),	O
and	O
were	O
mounted	O
on	O
slide	O
for	O
microscopy	O
.	O

5000	O
cells	O
were	O
analyzed	O
for	O
each	O
condition	O
and	O
results	O
were	O
expressed	O
as	O
MN	O
/	O
1000	O
cells	O
.	O

MN	O
smaller	O
than	O
one	O
-	O
third	O
the	O
diameter	O
of	O
the	O
nucleus	O
were	O
scored	O
under	O
a	O
fluorescent	O
microscope	O
at	O
630	O
×	O
magnification	O
.	O

3	O
.	O
2	O
MTT	O
Assay	O

Percentage	O
cell	O
viability	O
was	O
assessed	O
using	O
the	O
3	O
-(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)-	O
2	O
,	O
5	O
-	O
diphenyl	O
tetrazolium	O
bromide	O
(	O
MTT	O
)	O
assay	O
as	O
described	O
earlier	O
[	O
16	O
].	O

In	O
brief	O
,	O
the	O
cells	O
(	O
1	O
×	O
104	O
)	O
were	O
allowed	O
to	O
adhere	O
for	O
24	O
h	O
in	O
5	O
%	O
CO2	O
at	O
37	O
°	O
C	O
and	O
20	O
%	O
humidity	O
in	O
96	O
-	O
well	O
culture	O
plates	O
.	O

After	O
the	O
exposure	O
for	O
6h	O
,	O
12h	O
and	O
24h	O
,	O
MTT	O
(	O
5	O
mg	O
/	O
ml	O
of	O
stock	O
in	O
PBS	O
)	O
was	O
added	O
(	O
10	O
µl	O
/	O
well	O
in	O
100	O
µl	O
of	O
cell	O
suspension	O
),	O
and	O
plates	O
were	O
incubated	O
for	O
another	O
4h	O
.	O

At	O
the	O
end	O
of	O
incubation	O
period	O
,	O
the	O
reaction	O
mixture	O
was	O
carefully	O
taken	O
out	O
and	O
200	O
µl	O
of	O
dimethyl	O
sulfoxide	O
was	O
added	O
to	O
each	O
well	O
,	O
the	O
contents	O
were	O
mixed	O
well	O
by	O
pippeting	O
up	O
and	O
down	O
several	O
times	O
.	O

The	O
plates	O
were	O
kept	O
on	O
rocker	O
shaker	O
for	O
10	O
min	O
at	O
room	O
temperature	O
and	O
then	O
read	O
at	O
550	O
nm	O
using	O
multiwell	O
microplate	O
Reader	O
(	O
Multi	O
Skan	O
,	O
Thermo	O
Scientific	O
).	O

Untreated	O
sets	O
were	O
run	O
under	O
identical	O
conditions	O
and	O
served	O
as	O
basal	O
control	O
.	O

3	O
.	O
3	O
ROS	O
Assay	O

ROS	O
generation	O
was	O
assessed	O
in	O
A549	O
cells	O
using	O
2	O
',	O
7	O
'-	O
diclorodihydrofluorescein	O
di	O
-	O
acetate	O
(	O
DCFH	O
-	O
DA	O
,	O
Sigma	O
Aldrich	O
,	O
Missouri	O
,	O
USA	O
)	O
dye	O
as	O
fluorescence	O
agent	O
.	O

ROS	O
generation	O
was	O
performed	O
as	O
described	O
earlier	O
[	O
12	O
].	O

The	O
cells	O
(	O
1	O
×	O
104	O
per	O
well	O
)	O
were	O
seeded	O
in	O
96	O
-	O
well	O
black	O
bottom	O
culture	O
plates	O
and	O
allowed	O
to	O
adhere	O
them	O
for	O
24h	O
in	O
CO2	O
incubator	O
at	O
37	O
°	O
C	O
.	O

The	O
medium	O
was	O
then	O
aspirated	O
and	O
cells	O
were	O
exposed	O
to	O
different	O
conditions	O
as	O
describes	O
for	O
2h	O
,	O
6h	O
,	O
12h	O
and	O
24h	O
.	O

On	O
the	O
completion	O
of	O
respective	O
exposure	O
periods	O
,	O
cells	O
were	O
incubated	O
with	O
DCFH	O
-	O
DA	O
(	O
10	O
mM	O
)	O
for	O
30	O
min	O
at	O
37	O
°	O
C	O
.	O

The	O
reaction	O
mixture	O
was	O
then	O
aspirated	O
and	O
replaced	O
by	O
200	O
ml	O
of	O
PBS	O
in	O
each	O
well	O
.	O

The	O
plates	O
were	O
kept	O
on	O
rocker	O
shaker	O
for	O
10	O
min	O
at	O
room	O
temperature	O
in	O
the	O
dark	O
.	O

Fluorescence	O
intensity	O
was	O
measured	O
using	O
multiwell	O
microplate	O
reader	O
(	O
Multi	O
Skan	O
,	O
Thermo	O
Scientific	O
)	O
on	O
excitation	O
wavelength	O
at	O
485	O
nm	O
and	O
emission	O
wavelength	O
at	O
528	O
nm	O
.	O

The	O
data	O
were	O
expressed	O
as	O
percentage	O
of	O
the	O
unexposed	O
control	O
.	O

4	O
.	O
In	O
silico	O
study	O

4	O
.	O
1	O
Preparation	O
and	O
Validation	O
of	O
AHR	B-GP

PDB	O
structure	O
of	O
aryl	B-GP
hydrocarbon	I-GP
receptor	I-GP
(	O
AHR	B-GP
Uniprot	O
entry	O
-	O
P35869	O
)	O
is	O
not	O
available	O
in	O
the	O
PDB	O
databank	O
.	O

I	O
-	O
TASSER	O
[	O
17	O
]	O
online	O
server	O
was	O
utilized	O
for	O
the	O
ab	O
-	O
initio	O
modeling	O
to	O
build	O
the	O
3D	O
structure	O
of	O
AHR	B-GP
as	O
shown	O
in	O
Figure	O
1	O
,	O
and	O
validated	O
by	O
the	O
approach	O
of	O
Ramacharndran	O
Plot	O
by	O
using	O
RAMPAGE	O
[	O
18	O
].	O

AHR	B-GP
structure	O
as	O
predicted	O
with	O
help	O
of	O
I	O
-	O
TASSER	O
online	O
server	O
.	O

AHR	B-GP
3D	O
structure	O
has	O
been	O
submitted	O
in	O
Protein	O
Model	O
Data	O
Base	O
,	O
(	O
PMDB	O
ID	O
-	O
PM0078981	O
)	O
[	O
19	O
],	O
a	O
Protein	O
Data	O
Base	O
which	O
collects	O
three	O
dimensional	O
protein	O
models	O
obtained	O
by	O
structure	O
prediction	O
methods	O
.	O

4	O
.	O
2	O
Preparation	O
of	O
Benzo	O
[	O
a	O
]	O
Pyrene	O

The	O
SMILES	O
(	O
Simplified	O
Molecular	O
Input	O
Line	O
Entry	O
Specification	O
)	O
notations	O
of	O
the	O
BaP	O
were	O
obtained	O
from	O
the	O
ZINC	O
database	O
(	O
ZINC	O
ID	O
-	O
01530818	O
).	O

The	O
3D	O
-	O
structure	O
of	O
BaP	O
was	O
generated	O
de	O
novo	O
,	O
via	O
the	O
internet	O
(	O
http	O
://	O
molecular	O
-	O
networks	O
.	O
com	O
/	O
products	O
/	O
corina	O
),	O
by	O
program	O
CORINA	O
on	O
server	O
running	O
in	O
Computer	O
-	O
Chemie	O
-	O
Centrum	O
,	O
Universiy	O
of	O
Erlangen	O
-	O
Nurnburg	O
,	O
Germany	O
.	O

It	O
is	O
a	O
rule	O
-	O
and	O
data	O
-	O
base	O
system	O
,	O
that	O
automatically	O
generates	O
3D	O
atomic	O
coordinates	O
from	O
the	O
constitution	O
of	O
a	O
molecule	O
as	O
expressed	O
by	O
connection	O
table	O
or	O
linear	O
code	O
as	O
shown	O
in	O
Figure	O
2	O
.	O

BaP	O
structure	O
as	O
genrated	O
with	O
help	O
of	O
CORINA	O
online	O
server	O
.	O

4	O
.	O
3	O
Construction	O
of	O
Anatase	O
TiO2	O
Nanoparticle	O

After	O
studying	O
the	O
anatase	O
crystal	O
structure	O
,	O
we	O
found	O
that	O
anatase	O
is	O
the	O
thermodynamically	O
favored	O
phase	O
.	O

According	O
to	O
the	O
anatase	O
lattice	O
parameters	O
,	O
the	O
tetragonal	O
crystal	O
have	O
lengths	O
(	O
A	O
,	O
B	O
and	O
C	O
)	O
as	O
;	O
A	O
=	O
B	O
=	O
3	O
.	O
782	O
Å	O
,	O
C	O
=	O
9	O
.	O
502	O
.	O
Å	O
and	O
angles	O
(	O
alpha	O
,	O
beta	O
and	O
gamma	O
)	O
as	O
;	O
Alpha	O
=	O
beta	O
=	O
gamma	O
=	O
90o	O
[	O
20	O
].	O

The	O
Accelrys	O
Discovery	O
studio	O
2	O
.	O
5	O
program	O
was	O
found	O
to	O
be	O
the	O
most	O
suitable	O
software	O
for	O
the	O
designing	O
of	O
TiO2	O
anatase	O
crystal	O
structure	O
.	O

After	O
the	O
construction	O
of	O
Unit	O
cell	O
of	O
TiO2	O
anatase	O
by	O
using	O
the	O
anatase	O
lattice	O
parameters	O
,	O
a	O
surface	O
was	O
created	O
and	O
this	O
unit	O
cell	O
was	O
extended	O
in	O
the	O
desired	O
directions	O
(	O
axis	O
)	O
creating	O
a	O
new	O
surface	O
of	O
TiO2	O
comprising	O
[	O
1	O
,	O
0	O
,	O
1	O
]	O
of	O
5	O
unit	O
cells	O
in	O
×	O
direction	O
and	O
2	O
unit	O
cells	O
in	O
the	O
Z	O
direction	O
.	O

This	O
gave	O
a	O
surface	O
of	O
dimensions	O
1	O
.	O
891	O
×	O
0	O
.	O
3782	O
×	O
1	O
.	O
9004	O
nm3	O
as	O
shown	O
in	O
Figure	O
3	O
.	O

TiO2	O
NP	O
structure	O
as	O
constructed	O
with	O
help	O
of	O
DISCOVERY	O
STUDIO	O
2	O
.	O
5	O
.	O

4	O
.	O
4	O
Docking	O
Study	O

All	O
the	O
in	O
silico	O
docking	O
analyses	O
were	O
performed	O
using	O
PatchDock	O
[	O
21	O
].	O

The	O
AHR	B-GP
was	O
docked	O
with	O
the	O
BaP	O
,	O
as	O
well	O
as	O
TiO2	O
NP	O
.	O

The	O
resultant	O
pdb	O
file	O
obtained	O
after	O
AHR	B-GP
and	O
TiO2	O
NP	O
docking	O
was	O
used	O
as	O
AHR	B-GP
-	O
TiO2	O
NP	O
complex	O
,	O
and	O
was	O
docked	O
with	O
BaP	O
by	O
uploading	O
the	O
receptor	O
and	O
molecules	O
in	O
PatchDock	O
Server	O
,	O
an	O
automatic	O
server	O
for	O
molecular	O
docking	O
.	O

Clustering	O
RMSD	O
was	O
chosen	O
as	O
4	O
.	O
0	O
Å	O
.	O

5	O
.	O

Statistical	O
analysis	O

All	O
the	O
experiments	O
were	O
performed	O
in	O
triplicates	O
and	O
were	O
repeated	O
twice	O
.	O

The	O
final	O
results	O
were	O
expressed	O
as	O
mean	O
of	O
the	O
values	O
obtained	O
from	O
all	O
experiments	O
.	O

The	O
standard	O
error	O
of	O
mean	O
(	O
SEM	O
)	O
was	O
also	O
calculated	O
.	O

Statistical	O
analysis	O
was	O
performed	O
by	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
using	O
Newman	O
-	O
Keuls	O
test	O
to	O
compare	O
all	O
the	O
groups	O
by	O
graph	O
pad	O
prism3	O
.	O

In	O
all	O
the	O
cases	O
,	O
p	O
<	O
0	O
.	O
05	O
was	O
considered	O
as	O
significant	O
.	O

Results	O

1	O
.	O

Dose	O
optimization	O

Different	O
doses	O
of	O
BaP	O
(	O
10	O
µM	O
,	O
25	O
µM	O
,	O
50	O
µM	O
and	O
75	O
µM	O
)	O
were	O
tested	O
in	O
A	O
-	O
549	O
cells	O
to	O
determine	O
the	O
most	O
suitable	O
dose	O
for	O
each	O
assay	O
in	O
the	O
study	O
.	O

The	O
MN	O
induced	O
were	O
43	O
.	O
33	O
±	O
3	O
.	O
844	O
,	O
52	O
±	O
2	O
.	O
646	O
,	O
47	O
±	O
2	O
.	O
082	O
&	O
24	O
.	O
67	O
±	O
2	O
.	O
333	O
MN	O
/	O
1000	O
cells	O
at	O
10	O
µM	O
,	O
25	O
µM	O
,	O
50	O
µM	O
and	O
75	O
µM	O
BaP	O
concentrations	O
respectively	O
after	O
24h	O
exposure	O
,	O
against	O
5	O
±	O
1	O
.	O
528	O
MN	O
/	O
1000	O
in	O
control	O
(	O
unexposed	O
)	O
cells	O
as	O
shown	O
in	O
Figure	O
4	O
.	O

25	O
µM	O
concentration	O
was	O
selected	O
for	O
MN	O
assay	O
in	O
further	O
experimentation	O
as	O
highest	O
genotoxicity	O
was	O
observed	O
at	O
this	O
dose	O
,	O
above	O
this	O
concentration	O
BaP	O
became	O
cytotoxic	O
.	O

Number	O
of	O
micronucleus	O
/	O
1000	O
cells	O
,	O
induced	O
by	O
various	O
concentrations	O
of	O
BaP	O
after	O
24	O
h	O
exposure	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
considered	O
as	O
significant	O
.	O

BaP	O
:	O
Benzo	O
[	O
alpha	O
]	O
Pyrene	O
;	O
MN	O
:	O
Micronucleus	O
.	O

The	O
cell	O
viability	O
,	O
following	O
exposure	O
to	O
10	O
µM	O
,	O
25	O
µM	O
,	O
50	O
µM	O
and	O
75	O
µM	O
of	O
BaP	O
concentrations	O
was	O
observed	O
as	O
85	O
±	O
4	O
.	O
041	O
,	O
90	O
±	O
2	O
.	O
646	O
,	O
71	O
±	O
3	O
.	O
215	O
,	O
and	O
48	O
±	O
2	O
.	O
333	O
%	O
after	O
6h	O
,	O
83	O
±	O
2	O
.	O
43	O
,	O
80	O
±	O
3	O
.	O
44	O
,	O
68	O
±	O
4	O
.	O
152	O
,	O
and	O
37	O
.	O
68	O
±	O
3	O
.	O
423	O
%	O
after	O
12h	O
exposure	O
,	O
and	O
80	O
±	O
1	O
.	O
01	O
,	O
75	O
±	O
4	O
.	O
381	O
,	O
50	O
.	O
2	O
±	O
2	O
.	O
153	O
,	O
and	O
12	O
.	O
72	O
±	O
2	O
.	O
412	O
%	O
after	O
24h	O
exposure	O
respectively	O
,	O
against	O
control	O
(	O
unexposed	O
)	O
cells	O
,	O
as	O
shown	O
in	O
Figure	O
5	O
.	O

75	O
µM	O
concentration	O
was	O
selected	O
for	O
MTT	O
assay	O
in	O
further	O
experimentation	O
as	O
highest	O
cytotoxicity	O
was	O
observed	O
at	O
this	O
dose	O
.	O

Identification	O
of	O
cell	O
viability	O
after	O
6	O
,	O
12	O
&	O
24	O
h	O
of	O
exposure	O
to	O
various	O
concentrations	O
of	O
BaP	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
indicates	O
significance	O
.	O

MTT	O
:	O
3	O
-(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)-	O
2	O
,	O
5	O
-	O
diphenyl	O
tetrazolium	O
bromide	O
;	O
BaP	O
:	O
Benzo	O
[	O
alpha	O
]	O
Pyrene	O
.	O

ROS	O
generation	O
following	O
exposure	O
to	O
10	O
µM	O
,	O
25	O
µM	O
,	O
50	O
µM	O
and	O
75	O
µM	O
of	O
BaP	O
concentrations	O
were	O
observed	O
as	O
160	O
±	O
5	O
.	O
29	O
,	O
199	O
±	O
19	O
.	O
35	O
,	O
230	O
±	O
7	O
.	O
23	O
,	O
and	O
262	O
±	O
5	O
.	O
044	O
%	O
after	O
2h	O
,	O
162	O
±	O
7	O
.	O
42	O
,	O
212	O
±	O
8	O
.	O
76	O
,	O
234	O
±	O
8	O
.	O
66	O
,	O
and	O
230	O
±	O
5	O
.	O
77	O
%	O
after	O
6h	O
,	O
and	O
140	O
±	O
5	O
.	O
19	O
,	O
200	O
±	O
2	O
.	O
88	O
,	O
245	O
±	O
8	O
.	O
66	O
,	O
and	O
210	O
±	O
2	O
.	O
88	O
%	O
after	O
12h	O
of	O
exposure	O
and	O
130	O
±	O
6	O
.	O
35	O
,	O
170	O
±	O
5	O
.	O
77	O
,	O
225	O
±	O
8	O
.	O
56	O
,	O
and	O
140	O
±	O
2	O
.	O
517	O
%	O
after	O
24h	O
respectively	O
,	O
against	O
unexposed	O
cells	O
,	O
as	O
shown	O
in	O
Figure	O
6	O
.	O

50	O
µM	O
concentration	O
was	O
selected	O
for	O
ROS	O
generation	O
assay	O
in	O
further	O
experimentation	O
as	O
highest	O
ROS	O
induction	O
was	O
observed	O
at	O
this	O
dose	O
.	O

Percentage	O
change	O
in	O
ROS	O
generation	O
following	O
2	O
,	O
6	O
,	O
12	O
and	O
24	O
h	O
of	O
exposure	O
to	O
various	O
concentrations	O
of	O
BaP	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
considered	O
as	O
significant	O
.	O

BaP	O
:	O
Benzo	O
[	O
alpha	O
]	O
Pyrene	O
;	O
ROS	O
:	O
Reactive	O
Oxygen	O
Species	O
.	O

2	O
.	O

MN	O
Assay	O

Micronucleus	O
assay	O
was	O
performed	O
to	O
analyze	O
genotoxicity	O
in	O
different	O
experimental	O
sets	O
.	O

Different	O
doses	O
of	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and1	O
.	O
0	O
µg	O
/	O
ml	O
)	O
induced	O
slightly	O
higher	O
number	O
of	O
MN	O
(	O
6	O
±	O
1	O
.	O
155	O
,	O
7	O
.	O
66	O
±	O
0	O
.	O
8819	O
and	O
8	O
.	O
66	O
±	O
2	O
.	O
028	O
MN	O
/	O
1000	O
cells	O
respectively	O
)	O
as	O
compared	O
to	O
unexposed	O
control	O
(	O
5	O
±	O
0	O
.	O
5774	O
MN	O
/	O
1000	O
cells	O
).	O

The	O
highest	O
genotoxic	O
dose	O
(	O
25	O
µM	O
)	O
of	O
BaP	O
induced	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
high	O
numbers	O
of	O
MN	O
(	O
53	O
.	O
33	O
±	O
4	O
.	O
41	O
MN	O
/	O
1000	O
cells	O
).	O

Whereas	O
,	O
co	O
-	O
exposure	O
of	O
BaP	O
(	O
25	O
µM	O
)	O
and	O
different	O
doses	O
of	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
µg	O
/	O
ml	O
,	O
0	O
.	O
5	O
µg	O
/	O
ml	O
,	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
)	O
resulted	O
in	O
significant	O
reduction	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
of	O
MN	O
induction	O
(	O
31	O
.	O
67	O
±	O
4	O
.	O
41	O
,	O
37	O
±	O
2	O
.	O
887	O
,	O
and	O
41	O
.	O
67	O
±	O
2	O
.	O
603	O
MN	O
/	O
1000	O
cells	O
respectively	O
),	O
as	O
compared	O
to	O
BaP	O
exposed	O
cells	O
as	O
shown	O
in	O
Figure	O
7	O
.	O

Number	O
of	O
micronucleus	O
/	O
1000	O
cells	O
after	O
24	O
h	O
exposure	O
to	O
25	O
µM	O
BaP	O
,	O
to	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
of	O
TiO2	O
NPs	O
,	O
and	O
co	O
-	O
exposure	O
to	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
of	O
TiO2	O
NPs	O
along	O
with	O
25	O
µM	O
BaP	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
considered	O
as	O
significant	O
.	O
a	O
–	O
as	O
compared	O
to	O
control	O
,	O
b	O
-	O
as	O
compared	O
to	O
BaP	O
treated	O
.	O

BaP	O
:	O
Benzo	O
[	O
alpha	O
]	O
Pyrene	O
;	O
MN	O
:	O
Micronucleus	O
;	O
TiO2	O
NPs	O
:	O
Titanium	O
Dioxide	O
Nanoparticles	O
.	O

3	O
.	O

Cytotoxicity	O
assay	O

MTT	O
assay	O
was	O
performed	O
to	O
analyze	O
the	O
cytotoxicity	O
in	O
different	O
experimental	O
sets	O
.	O

TiO2	O
NPs	O
exposure	O
resulted	O
in	O
very	O
slight	O
cytotoxicity	O
.	O

The	O
%	O
of	O
viable	O
cell	O
observed	O
after	O
exposure	O
to	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and1	O
.	O
0	O
µg	O
/	O
ml	O
)	O
was	O
98	O
.	O
64	O
±	O
0	O
.	O
2022	O
,	O
97	O
.	O
6	O
±	O
0	O
.	O
3711	O
,	O
and	O
96	O
.	O
73	O
±	O
0	O
.	O
1802	O
after	O
6h	O
,	O
97	O
.	O
45	O
±	O
0	O
.	O
2461	O
,	O
96	O
.	O
93	O
±	O
0	O
.	O
3169	O
,	O
and	O
94	O
.	O
83	O
±	O
0	O
.	O
5185	O
after	O
12	O
h	O
,	O
and	O
95	O
.	O
3	O
±	O
0	O
.	O
6582	O
,	O
93	O
.	O
77	O
±	O
0	O
.	O
2963	O
,	O
and	O
92	O
.	O
47	O
±	O
0	O
.	O
2767	O
after	O
24h	O
respectively	O
.	O

But	O
,	O
BaP	O
exposure	O
at	O
selected	O
dose	O
of	O
75	O
µM	O
showed	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
reduction	O
in	O
cell	O
viability	O
,	O
which	O
as	O
46	O
.	O
51	O
±	O
1	O
.	O
147	O
%	O
after	O
6	O
h	O
exposure	O
,	O
the	O
effect	O
became	O
more	O
intense	O
after	O
12h	O
(	O
39	O
.	O
12	O
±	O
1	O
.	O
33	O
%)	O
and	O
24h	O
(	O
10	O
.	O
41	O
±	O
0	O
.	O
494	O
%)	O
exposure	O
.	O

Whereas	O
,	O
co	O
-	O
exposure	O
of	O
BaP	O
(	O
75	O
µM	O
)	O
with	O
different	O
doses	O
of	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
µg	O
/	O
ml	O
,	O
0	O
.	O
5	O
µg	O
/	O
ml	O
,	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
),	O
resulted	O
in	O
significant	O
increase	O
in	O
cell	O
viability	O
(	O
77	O
.	O
7	O
±	O
0	O
.	O
60	O
,	O
71	O
.	O
72	O
±	O
0	O
.	O
52	O
,	O
and	O
70	O
.	O
88	O
±	O
0	O
.	O
56	O
%	O
at	O
6h	O
,	O
68	O
.	O
16	O
±	O
0	O
.	O
85	O
,	O
63	O
.	O
31	O
±	O
0	O
.	O
94	O
,	O
and	O
60	O
.	O
12	O
±	O
0	O
.	O
82	O
%	O
at	O
12h	O
and	O
65	O
.	O
85	O
±	O
1	O
.	O
20	O
,	O
61	O
.	O
73	O
±	O
0	O
.	O
82	O
,	O
and	O
59	O
.	O
53	O
±	O
1	O
.	O
114	O
%	O
at	O
24h	O
,	O
respectively	O
)	O
as	O
compared	O
to	O
BaP	O
exposed	O
cells	O
as	O
shown	O
in	O
Figure	O
8	O
.	O

Percentage	O
viability	O
of	O
the	O
cells	O
exposed	O
to	O
75	O
µM	O
BaP	O
,	O
to	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
of	O
TiO2	O
NPs	O
and	O
co	O
-	O
exposure	O
to	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
of	O
TiO2	O
NPs	O
along	O
with	O
75	O
µM	O
,	O
for	O
6	O
,	O
12	O
&	O
24	O
h	O
,	O
as	O
measured	O
by	O
MTT	O
assay	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
indicates	O
significance	O
.	O
a	O
–	O
as	O
compared	O
to	O
control	O
,	O
b	O
-	O
as	O
compared	O
to	O
BaP	O
treated	O
.	O

MTT	O
:	O
3	O
-(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)-	O
2	O
,	O
5	O
-	O
diphenyl	O
tetrazolium	O
bromide	O
;	O
BaP	O
:	O
Benzo	O
[	O
alpha	O
]	O
Pyrene	O
,	O
TiO2	O
NPs	O
:	O
titanium	O
dioxide	O
nanoparticles	O
.	O

4	O
.	O

Oxidative	O
Stress	O

DCFH	O
-	O
DA	O
staining	O
was	O
performed	O
to	O
analyze	O
ROS	O
generation	O
in	O
different	O
experimental	O
sets	O
.	O

The	O
%	O
of	O
ROS	O
observed	O
after	O
exposure	O
to	O
different	O
doses	O
of	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and1	O
.	O
0	O
µg	O
/	O
ml	O
)	O
was	O
102	O
.	O
5	O
±	O
2	O
.	O
201	O
,	O
103	O
.	O
5	O
±	O
2	O
.	O
871	O
,	O
and	O
103	O
.	O
3	O
±	O
3	O
.	O
808	O
%,	O
respectively	O
after	O
2h	O
,	O
104	O
.	O
5	O
±	O
0	O
.	O
2999	O
,	O
105	O
±	O
0	O
.	O
4533	O
,	O
and	O
107	O
.	O
5	O
±	O
0	O
.	O
3143	O
%	O
after	O
6h	O
,	O
and	O
104	O
.	O
5	O
±	O
0	O
.	O
2999	O
,	O
105	O
±	O
0	O
.	O
4533	O
,	O
and	O
107	O
.	O
5	O
±	O
0	O
.	O
3143	O
%	O
after	O
12h	O
,	O
104	O
.	O
6	O
±	O
0	O
.	O
8764	O
,	O
106	O
.	O
5	O
±	O
1	O
.	O
459	O
and	O
108	O
.	O
6	O
±	O
0	O
.	O
2267	O
%	O
after	O
24h	O
,	O
respectively	O
.	O

The	O
exposure	O
to	O
selected	O
dose	O
(	O
50	O
µM	O
)	O
of	O
BaP	O
induced	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
higher	O
ROS	O
(	O
229	O
.	O
2	O
±	O
5	O
.	O
174	O
%	O
after	O
2h	O
,	O
240	O
.	O
2	O
±	O
2	O
.	O
976	O
%	O
after	O
6h	O
,	O
246	O
.	O
2	O
±	O
1	O
.	O
178	O
%	O
after	O
12h	O
,	O
and	O
220	O
.	O
2	O
±	O
1	O
.	O
749	O
%	O
after	O
24h	O
,	O
respectively	O
).	O

Whereas	O
,	O
the	O
co	O
-	O
exposure	O
of	O
BaP	O
(	O
50	O
µM	O
)	O
with	O
different	O
doses	O
of	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
µg	O
/	O
ml	O
,	O
0	O
.	O
5	O
µg	O
/	O
ml	O
,	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
)	O
resulted	O
in	O
significant	O
reduction	O
in	O
ROS	O
generation	O
(	O
154	O
.	O
9	O
±	O
5	O
.	O
71	O
,	O
158	O
.	O
2	O
±	O
3	O
.	O
17	O
,	O
and	O
161	O
.	O
4	O
±	O
3	O
.	O
17	O
%	O
after	O
2h	O
,	O
155	O
.	O
7	O
±	O
1	O
.	O
78	O
,	O
156	O
.	O
6	O
±	O
1	O
.	O
79	O
,	O
and	O
165	O
.	O
9	O
±	O
4	O
.	O
14	O
%	O
after	O
6h	O
,	O
156	O
.	O
1	O
±	O
1	O
.	O
76	O
,	O
156	O
.	O
3	O
±	O
0	O
.	O
24	O
,	O
and	O
162	O
.	O
6	O
±	O
0	O
.	O
89	O
after	O
12h	O
,	O
and	O
152	O
.	O
5	O
±	O
1	O
.	O
16	O
,	O
153	O
.	O
6	O
±	O
0	O
.	O
67	O
,	O
and	O
157	O
.	O
6	O
±	O
1	O
.	O
16	O
%	O
after	O
24h	O
,	O
respectively	O
)	O
as	O
compared	O
to	O
ROS	O
generation	O
by	O
BaP	O
alone	O
at	O
all	O
time	O
periods	O
,	O
as	O
shown	O
in	O
Figure	O
9	O
.	O

Percentage	O
changes	O
in	O
ROS	O
generation	O
following	O
6	O
,	O
12	O
and	O
24	O
h	O
exposure	O
to	O
50	O
µM	O
BaP	O
,	O
to	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
of	O
TiO2	O
NPs	O
and	O
co	O
-	O
exposure	O
to	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
of	O
TiO2	O
NPs	O
along	O
with	O
50	O
µM	O
BaP	O
,	O
as	O
assessed	O
by	O
DCFH	O
-	O
DA	O
dye	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
considered	O
as	O
significant	O
.	O
a	O
–	O
as	O
compared	O
to	O
control	O
,	O
b	O
-	O
as	O
compared	O
to	O
BaP	O
treated	O
.	O

BaP	O
:	O
Benzo	O
[	O
alpha	O
]	O
Pyrene	O
;	O
ROS	O
:	O
Reactive	O
Oxygen	O
Species	O
;	O
TiO2	O
NPs	O
:	O
titanium	O
dioxide	O
nanoparticles	O
.	O

5	O
.	O

Protein	O
Structure	O
Validation	O

3D	O
structure	O
model	O
of	O
AHR	B-GP
was	O
generated	O
using	O
I	O
-	O
TASSER	O
online	O
server	O
(	O
ab	O
initio	O
modeling	O
),	O
as	O
shown	O
in	O
Figure	O
1	O
.	O

The	O
model	O
was	O
validated	O
using	O
RAMPAGE	O
by	O
Ramachandran	O
plot	O
approach	O
.	O

The	O
torsion	O
angles	O
of	O
the	O
3D	O
structure	O
of	O
AHR	B-GP
showed	O
83	O
.	O
5	O
%	O
amino	O
acid	O
residues	O
in	O
the	O
favored	O
regions	O
as	O
shown	O
in	O
Figure	O
10	O
.	O

Modeled	O
structures	O
of	O
AHR	B-GP
showing	O
83	O
.	O
5	O
%	O
of	O
amino	O
acid	O
residues	O
in	O
favored	O
region	O
of	O
Ramachandran	O
plot	O
.	O

6	O
.	O
In	O
Silico	O
Docking	O
Studies	O
of	O
TiO2	O
NP	O
and	O
BAP	O

In	O
the	O
present	O
study	O
,	O
the	O
orientation	O
and	O
binding	O
affinity	O
(	O
in	O
terms	O
of	O
the	O
total	O
docking	O
score	O
and	O
binding	O
residues	O
)	O
of	O
TiO2	O
NP	O
and	O
BaP	O
was	O
explored	O
with	O
AHR	B-GP
.	O

TiO2	O
NP	O
showed	O
high	O
binding	O
affinity	O
with	O
AHR	B-GP
with	O
a	O
docking	O
score	O
of	O
12074	O
,	O
as	O
compared	O
to	O
the	O
docking	O
score	O
of	O
BaP	O
with	O
AHR	B-GP
(	O
4600	O
).	O

Docking	O
score	O
of	O
BaP	O
with	O
AHR	B-GP
-	O
TiO2	O
NP	O
complex	O
was	O
4710	O
.	O

The	O
chemical	O
nature	O
of	O
binding	O
site	O
residues	O
of	O
AHR	B-GP
within	O
a	O
radius	O
of	O
4A	O
°	O
with	O
BaP	O
showed	O
hydrophobic	O
interaction	O
with	O
Pro180	O
,	O
Ser181	O
,	O
Cys183	O
,	O
Gly187	O
,	O
Leu196	O
,	O
Val200	O
,	O
Asn204	O
,	O
Leu259	O
,	O
Pro260	O
,	O
Leu265	O
,	O
Ala269	O
,	O
Thr270	O
,	O
Leu272	O
and	O
Pro274	O
residues	O
,	O
as	O
shown	O
in	O
Figure	O
11	O
.	O

Binding	O
Sites	O
of	O
AHR	B-GP
-	O
BaP	O
complex	O
.	O

(	O
Pro180	O
,	O
Ser181	O
,	O
Cys183	O
,	O
Gly187	O
,	O
Leu196	O
,	O
Val200	O
,	O
Asn204	O
,	O
Leu259	O
,	O
Pro260	O
,	O
Leu265	O
,	O
Ala269	O
,	O
Thr270	O
,	O
Leu272	O
,	O
Pro274	O
).	O

The	O
chemical	O
nature	O
of	O
binding	O
site	O
residues	O
of	O
AHR	B-GP
within	O
a	O
radius	O
of	O
4A	O
°	O
with	O
TiO2	O
NP	O
showed	O
hydrogen	O
bond	O
interaction	O
with	O
Gln667	O
-	O
NE2	O
:	O
O98	O
bond	O
length	O
3	O
.	O
11	O
Ǻ	O
,	O
Gln667	O
-	O
N	O
:	O
O38	O
bond	O
length	O
2	O
.	O
53	O
Ǻ	O
,	O
Gln	O
383	O
-	O
NE2	O
:	O
O75	O
bond	O
length	O
1	O
.	O
94	O
Ǻ	O
,	O
Asp144N	O
:	O
O4	O
bond	O
length	O
2	O
.	O
91	O
Å	O
,	O
Ser	O
682	O
:	O
OG	O
:	O
O19	O
bond	O
length	O
3	O
.	O
26	O
Å	O
,	O
Gln149	O
NE2	O
:	O
O19	O
bond	O
length	O
2	O
.	O
45	O
Å	O
,	O
Try	O
696	O
CZ	O
-	O
OH	O
:	O
O5	O
bond	O
length	O
3	O
.	O
08	O
Å	O
&	O
O8	O
bond	O
length	O
3	O
.	O
08	O
Å	O
and	O
hydrophobic	O
interaction	O
with	O
Tyr	O
145	O
,	O
Ser	O
151	O
,	O
Phe	O
148	O
,	O
Leu	O
369	O
,	O
Asn	O
673	O
.	O

Asn	O
366	O
,	O
Agr	O
384	O
,	O
Pro	O
385	O
,	O
Leu	O
413	O
,	O
Try	O
719	O
,	O
Phe	O
406	O
,	O
Glu	O
488	O
,	O
Pro	O
665	O
,	O
Gln	O
671	O
&	O
Ser	O
682	O
,	O
as	O
shown	O
in	O
Figure	O
12	O
.	O

Binding	O
Sites	O
of	O
AHR	B-GP
-	O
TiO2	O
NP	O
complex	O
.	O

(	O
Tyr	O
145	O
,	O
Ser	O
151	O
,	O
Phe	O
148	O
,	O
Leu	O
369	O
,	O
Asn	O
673	O
.	O

Asn	O
366	O
,	O
Agr	O
384	O
,	O
Pro	O
385	O
,	O
Leu	O
413	O
,	O
Try	O
719	O
,	O
Gln383	O
,	O
Phe	O
406	O
,	O
Glu	O
488	O
,	O
Pro	O
665	O
,	O
Gln	O
667	O
,	O
Tyr	O
696	O
,	O
Gln	O
671	O
,	O
Asp	O
144	O
,	O
Ser	O
682	O
,	O
Gln	O
149	O
).	O

Whereas	O
,	O
the	O
BaP	O
when	O
docked	O
with	O
AHR	B-GP
-	O
TiO2	O
NP	O
complex	O
was	O
adsorbed	O
at	O
the	O
surface	O
of	O
TiO2	O
NP	O
,	O
as	O
shown	O
in	O
Figure	O
13	O
.	O

The	O
chemical	O
nature	O
of	O
binding	O
site	O
residues	O
of	O
AHR	B-GP
-	O
TiO2	O
NP	O
complex	O
within	O
a	O
radius	O
of	O
4A	O
°,	O
showed	O
the	O
hydrophobic	O
interaction	O
with	O
Gln	O
666	O
,	O
Try	O
719	O
,	O
Phe	O
700	O
,	O
Pro	O
669	O
,	O
Gln	O
698	O
,	O
Thr	O
408	O
,	O
Phe	O
406	O
,	O
Phe	O
675	O
,	O
Thr	O
696	O
.	O

Binding	O
Sites	O
of	O
AHR	B-GP
-	O
TiO2	O
NP	O
complex	O
&	O
BaP	O
.	O

(	O
Gln	O
666	O
,	O
Try	O
719	O
,	O
Phe	O
700	O
,	O
Pro	O
669	O
,	O
Gln	O
698	O
,	O
Thr	O
408	O
,	O
Phe	O
406	O
,	O
Phe	O
675	O
,	O
Thr	O
696	O
).	O

Discussion	O

The	O
present	O
study	O
was	O
designed	O
to	O
explore	O
the	O
probability	O
of	O
protective	O
application	O
of	O
nanoparticles	O
against	O
environmental	O
carcinogen	O
induced	O
toxicity	O
.	O

The	O
doses	O
of	O
BaP	O
,	O
the	O
reference	O
carcinogen	O
in	O
the	O
study	O
,	O
were	O
optimized	O
for	O
MN	O
,	O
MTT	O
and	O
ROS	O
generation	O
assays	O
in	O
A549	O
cells	O
.	O

The	O
BaP	O
exposure	O
caused	O
significant	O
reduction	O
in	O
cell	O
viability	O
,	O
which	O
was	O
dependent	O
on	O
period	O
of	O
exposure	O
and	O
was	O
highest	O
with	O
75	O
µM	O
at	O
24h	O
(	O
10	O
.	O
41	O
±.	O
494	O
%).	O

This	O
effect	O
could	O
be	O
attributed	O
to	O
enhanced	O
production	O
of	O
ROS	O
as	O
a	O
result	O
of	O
BaP	O
exposure	O
which	O
was	O
found	O
to	O
be	O
highest	O
with	O
50	O
µM	O
at	O
12h	O
(	O
246	O
.	O
9	O
±	O
1	O
.	O
178	O
%).	O

Further	O
,	O
ROS	O
generation	O
might	O
have	O
caused	O
the	O
DNA	O
damage	O
which	O
was	O
highest	O
with	O
25	O
µM	O
at	O
24h	O
(	O
53	O
.	O
33	O
±	O
4	O
.	O
41MN	O
/	O
1000	O
cells	O
).	O
Which	O
is	O
in	O
accordance	O
with	O
the	O
results	O
of	O
past	O
toxicological	O
studies	O
of	O
BaP	O
[	O
22	O
].	O

The	O
doses	O
of	O
25	O
µM	O
for	O
MN	O
assay	O
,	O
75	O
µM	O
for	O
MTT	O
assay	O
and	O
50	O
µM	O
for	O
ROS	O
generation	O
assay	O
were	O
selected	O
,	O
as	O
maximum	O
effects	O
were	O
observed	O
at	O
these	O
doses	O
in	O
respective	O
assays	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
protective	O
effect	O
of	O
nanoparticles	O
,	O
A549	O
cells	O
were	O
co	O
-	O
exposed	O
to	O
some	O
non	O
-	O
toxic	O
doses	O
of	O
TiO2	O
NPs	O
(	O
0	O
.	O
1	O
,	O
0	O
.	O
5	O
and1	O
.	O
0	O
µg	O
/	O
ml	O
)	O
along	O
with	O
BaP	O
.	O

At	O
all	O
doses	O
,	O
the	O
TiO2	O
NPs	O
offered	O
protection	O
and	O
raised	O
the	O
viability	O
of	O
A549	O
cells	O
as	O
compared	O
to	O
viability	O
in	O
only	O
BaP	O
exposed	O
cells	O
as	O
measured	O
by	O
MTT	O
assay	O
after	O
co	O
-	O
exposure	O
.	O

The	O
protective	O
effect	O
was	O
slightly	O
higher	O
with	O
0	O
.	O
1	O
µg	O
/	O
ml	O
concentration	O
of	O
TiO2	O
NPs	O
than	O
0	O
.	O
5	O
µg	O
/	O
ml	O
and	O
1	O
.	O
0	O
µg	O
/	O
ml	O
TiO2	O
NPs	O
.	O

Similarly	O
,	O
co	O
-	O
exposure	O
of	O
all	O
three	O
doses	O
of	O
TiO2	O
NPs	O
caused	O
significant	O
lowering	O
in	O
ROS	O
production	O
in	O
BaP	O
exposed	O
A549	O
cells	O
at	O
all	O
time	O
periods	O
.	O

Again	O
,	O
the	O
effect	O
of	O
0	O
.	O
1	O
µg	O
/	O
ml	O
concentration	O
of	O
TiO2	O
NPs	O
was	O
marginally	O
higher	O
as	O
compared	O
to	O
0	O
.	O
5	O
µg	O
/	O
ml	O
and	O
1	O
µg	O
/	O
ml	O
TiO2	O
NPs	O
.	O

Similar	O
effects	O
were	O
observed	O
in	O
the	O
MN	O
assay	O
also	O
,	O
where	O
co	O
-	O
exposure	O
of	O
all	O
three	O
doses	O
of	O
TiO2	O
NPs	O
caused	O
significant	O
reduction	O
in	O
MN	O
induction	O
by	O
BaP	O
in	O
A549	O
cells	O
.	O

Again	O
,	O
the	O
effect	O
of	O
0	O
.	O
1	O
µg	O
/	O
ml	O
concentration	O
of	O
TiO2	O
NPs	O
was	O
marginally	O
higher	O
as	O
compared	O
to	O
0	O
.	O
5	O
µg	O
/	O
ml	O
and	O
1	O
µg	O
/	O
ml	O
of	O
TiO2	O
NPs	O
.	O

All	O
three	O
end	O
points	O
used	O
for	O
study	O
depicted	O
clear	O
cut	O
reduction	O
in	O
the	O
toxicity	O
of	O
BaP	O
,	O
which	O
indicated	O
the	O
protective	O
potential	O
of	O
TiO2	O
NPs	O
in	O
low	O
dose	O
.	O

In	O
silico	O
approach	O
was	O
applied	O
in	O
order	O
to	O
explore	O
the	O
probable	O
mechanism	O
by	O
which	O
TiO2	O
NP	O
provided	O
protection	O
against	O
BaP	O
induced	O
toxicity	O
.	O

Previous	O
studies	O
have	O
established	O
that	O
AHR	B-GP
is	O
responsible	O
for	O
the	O
entry	O
and	O
regulation	O
of	O
the	O
enzymatic	O
metabolism	O
of	O
BaP	O
to	O
Benzo	O
[	O
a	O
]	O
pyrene	O
-	O
7	O
,	O
8	O
-	O
diol	O
-	O
9	O
,	O
10	O
-	O
epoxides	O
(	O
BPDE	O
),	O
a	O
crucial	O
carcinogenic	O
metabolite	O
of	O
BaP	O
,	O
which	O
reacts	O
primarily	O
with	O
the	O
N2	O
position	O
of	O
guanine	O
residues	O
and	O
to	O
a	O
minor	O
coverage	O
with	O
the	O
N6	O
position	O
of	O
adenine	O
residues	O
in	O
DNA	O
[	O
8	O
]	O
as	O
shown	O
in	O
Figure	O
14A	O
.	O

BPDE	O
forms	O
bulky	O
adducts	O
with	O
DNA	O
which	O
blocks	O
DNA	O
synthesis	O
during	O
replication	O
by	O
high	O
fidelity	O
DNA	B-GP
polymerases	I-GP
[	O
3	O
].	O

Role	O
of	O
AHR	B-GP
in	O
BaP	O
internalization	O
.	O

(	O
A	O
)	O
Internalization	O
of	O
BaP	O
in	O
to	O
cell	O
through	O
AHR	B-GP
,	O
metabolic	O
conversion	O
to	O
BPDE	O
and	O
interaction	O
of	O
BPDE	O
with	O
DNA	O
.	O

(	O
B	O
)	O
Preferential	O
binding	O
of	O
TiO2NP	O
with	O
AHR	B-GP
.	O

TiO2	O
NP	O
bound	O
to	O
AHR	B-GP
blocks	O
the	O
internalization	O
of	O
BaP	O
,	O
preventing	O
its	O
metabolic	O
conversion	O
to	O
BPDE	O
and	O
finally	O
avoiding	O
DNA	O
damage	O
.	O

The	O
docking	O
study	O
,	O
performed	O
to	O
determine	O
the	O
binding	O
abilities	O
of	O
BaP	O
and	O
TiO2	O
NPs	O
with	O
AHR	B-GP
,	O
revealed	O
that	O
TiO2	O
NP	O
bind	O
with	O
much	O
higher	O
molecular	O
docking	O
score	O
with	O
AHR	B-GP
(	O
12074	O
)	O
as	O
compared	O
with	O
docking	O
score	O
of	O
BaP	O
with	O
AHR	B-GP
(	O
4600	O
).	O

This	O
establishes	O
a	O
strong	O
possibility	O
of	O
preferential	O
binding	O
of	O
TiO2	O
NP	O
over	O
BaP	O
with	O
AHR	B-GP
,	O
incase	O
both	O
TiO2	O
NP	O
and	O
BaP	O
are	O
present	O
together	O
in	O
cell	O
vicinity	O
.	O

Further	O
,	O
to	O
investigate	O
how	O
AHR	B-GP
might	O
respond	O
to	O
BaP	O
when	O
TiO2	O
NP	O
is	O
already	O
bound	O
to	O
AHR	B-GP
,	O
the	O
BaP	O
was	O
docked	O
with	O
AHR	B-GP
-	O
TiO2	O
complex	O
.	O

The	O
BaP	O
was	O
adsorbed	O
strongly	O
at	O
the	O
TiO2	O
NP	O
(	O
score	O
4710	O
)	O
and	O
not	O
at	O
its	O
original	O
binding	O
site	O
at	O
AHR	B-GP
,	O
as	O
shown	O
in	O
Figure	O
14B	O
.	O

Previous	O
Studies	O
have	O
also	O
shown	O
a	O
strong	O
adsorption	O
potential	O
of	O
TiO2	O
NP	O
towards	O
PAHs	O
and	O
some	O
other	O
chemical	O
carcinogens	O
present	O
in	O
cigarette	O
[	O
9	O
],	O
[	O
11	O
].	O

In	O
present	O
case	O
also	O
strong	O
adsorption	O
potential	O
of	O
TiO2	O
NP	O
might	O
have	O
caused	O
the	O
shifting	O
in	O
binding	O
position	O
of	O
BaP	O
from	O
AHR	B-GP
to	O
TiO2	O
bound	O
to	O
AHR	B-GP
.	O

Once	O
a	O
bulk	O
substance	O
is	O
brought	O
to	O
nano	O
-	O
size	O
,	O
it	O
loses	O
its	O
surface	O
atomic	O
coordinates	O
thereby	O
increasing	O
free	O
surface	O
energy	O
.	O

The	O
stronger	O
binding	O
of	O
the	O
TiO2	O
NP	O
on	O
AHR	B-GP
as	O
well	O
as	O
adsorption	O
of	O
BaP	O
on	O
TiO2	O
surface	O
could	O
be	O
an	O
effect	O
of	O
nanosized	O
TiO2	O
in	O
order	O
to	O
minimize	O
high	O
free	O
surface	O
energy	O
,	O
to	O
accomplish	O
the	O
atomic	O
coordination	O
at	O
the	O
surface	O
and	O
to	O
establish	O
electronic	O
neutrality	O
[	O
23	O
].	O

Another	O
probable	O
reason	O
for	O
the	O
reduced	O
toxic	O
effect	O
of	O
co	O
-	O
exposure	O
could	O
be	O
the	O
direct	O
adsorption	O
of	O
BaP	O
onto	O
TiO2	O
nanoparticles	O
itself	O
,	O
rendering	O
BaP	O
unavailable	O
to	O
its	O
target	O
molecules	O
,	O
which	O
requires	O
further	O
in	O
depth	O
analysis	O
.	O

Conclusion	O

The	O
present	O
study	O
clearly	O
describes	O
the	O
attenuation	O
of	O
BaP	O
induced	O
toxicity	O
by	O
TiO2	O
nanoparticles	O
in	O
A549	O
cells	O
,	O
along	O
with	O
the	O
probable	O
mechanism	O
of	O
TiO2	O
NPs	O
protection	O
against	O
BaP	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
very	O
first	O
study	O
suggesting	O
future	O
prophylactic	O
application	O
of	O
nanoparticles	O
as	O
guardian	O
against	O
the	O
chemical	O
carcinogens	O
at	O
the	O
molecular	O
/	O
cellular	O
level	O
.	O

We	O
are	O
in	O
process	O
of	O
further	O
investigating	O
whether	O
TiO2	O
NPs	O
are	O
capable	O
of	O
protecting	O
cells	O
against	O
other	O
chemical	O
carcinogens	O
also	O
?	O

And	O
if	O
this	O
process	O
of	O
protection	O
can	O
be	O
further	O
enhanced	O
by	O
modifying	O
the	O
surface	O
chemistry	O
of	O
TiO2	O
NPs	O
.	O

Also	O
,	O
we	O
are	O
exploring	O
the	O
capacities	O
of	O
other	O
nanoparticles	O
like	O
CNT	O
,	O
Fullerene	O
etc	O
.	O
for	O
their	O
potential	O
to	O
provide	O
protection	O
against	O
chemical	O
carcinogens	O
.	O

